Bain Capital Affiliate Discloses 20.3% Stake in Kailera Therapeutics Post-IPO, Plans Active Role
KLRA is trading near its 52-week low of $23.65 (5.3% above the low) on elevated volume (2.3× avg).
Summary
BCPE Perseus Investor, LP, an affiliate of Bain Capital, has disclosed a 20.3% beneficial ownership stake in Kailera Therapeutics following its IPO, signaling active involvement in the company's strategic direction.
Key Events · Ownership and Investor Activity · KLRA
-
Significant Post-IPO Stake
BCPE Perseus Investor, LP, an affiliate of Bain Capital, now beneficially owns 26,255,581 shares, representing 20.27% of Kailera Therapeutics' common stock.
-
Substantial Investment
The stake includes a purchase of 8,398,438 shares at the IPO price of $16.00 per share on April 20, 2026, for a total of $134,375,008. This follows the conversion of prior preferred stock holdings.
-
Active Investor Role
The reporting person intends to take an active role in working with the Issuer's management and Board on operational, financial, and strategic initiatives. Andrew Kaplan, a Partner of Bain Capital Investors, LLC, is a member of the Issuer's board of directors.
-
Lock-Up Agreement
The investor is subject to a 180-day lock-up agreement, restricting the sale or transfer of shares post-IPO, demonstrating commitment.
Analysis · KLRA · Life Sciences
This Schedule 13D filing reveals that BCPE Perseus Investor, LP, an affiliate of Bain Capital, now beneficially owns 20.3% of Kailera Therapeutics' common stock. This significant stake was established through the conversion of preferred stock and a post-IPO purchase of 8.4 million shares at the IPO price of $16.00, totaling over $134 million. The filing indicates that Bain Capital intends to take an active role in the company's operational, financial, and strategic initiatives, reinforced by Andrew Kaplan, a Bain Capital Partner, serving on the board. This disclosure provides crucial insight into the post-IPO ownership structure and the influence of a major institutional investor, suggesting a strong vote of confidence and potential strategic guidance for the newly public company. The lock-up agreement for 180 days further demonstrates commitment.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KLRA was trading at $24.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $23.65 to $28.23. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.